TO STUDY THE CLINICAL EFFICACY OF PATHOGENETIC THERAPY IN WOMEN WITH GENITAL ENDOMETRIOSIS.

article OA: green CC0

Abstract

Endometriosis is a chronic hormone—dependent disease characterized by an inflammatory reaction [1,2]. The chronic, progressive, and recurrent nature of endometriosis makes it extremely urgent to search for new areas of targeted therapy for genital endometriosis that have high therapeutic efficacy and minimal side effects. Currently, the standard for specific therapy of endometriosis is the use of dienogest 2 mg, which is a hybrid progestogen that combines the best properties of the norsteroid and progesterone groups [5,7]. Currently, the main goal of modern therapy for genital endometriosis is not only the suppression of the level of estrogens synthesized by the ovaries, but also the pathogenetic effect on the site of endometriosis itself (suppression of local estrogen production, overcoming progesterone resistance, antiproliferative and antiangiogenic effects, increased apoptosis).
Full text 1,170 characters · extracted from oa-doi-fallback · click to expand
TO STUDY THE CLINICAL EFFICACY OF PATHOGENETIC THERAPY IN WOMEN WITH GENITAL ENDOMETRIOSIS. Authors/Creators Description Endometriosis is a chronic hormone—dependent disease characterized by an inflammatory reaction [1,2]. The chronic, progressive, and recurrent nature of endometriosis makes it extremely urgent to search for new areas of targeted therapy for genital endometriosis that have high therapeutic efficacy and minimal side effects. Currently, the standard for specific therapy of endometriosis is the use of dienogest 2 mg, which is a hybrid progestogen that combines the best properties of the norsteroid and progesterone groups [5,7]. Currently, the main goal of modern therapy for genital endometriosis is not only the suppression of the level of estrogens synthesized by the ovaries, but also the pathogenetic effect on the site of endometriosis itself (suppression of local estrogen production, overcoming progesterone resistance, antiproliferative and antiangiogenic effects, increased apoptosis). Files ARIMS 4220.pdf Files (618.6 kB) | Name | Size | Download all | |---|---|---| | md5:e5aa27690a1a91547a788ae5bc1092ed | 618.6 kB | Preview Download |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-05-10T10:26:51.820283+00:00
License: CC0 · commercial use OK